Placebo-controlled study of gabapentin treatment of panic disorder

Journal of Clinical Psychopharmacology

Volumn 20, Issue 4, 2000, Pages 467-471

  Pande, Atul C ^a   Pollack, Mark H ^b   Crockatt, Jerri ^a   Greiner, Martha ^a   Chouinard, Guy ^c   Lydiard, R Bruce ^e   Taylor, C Barr ^f   Dager, Stephen R ^d   Shiovitz, Thomas ^g  

^a PFIZER INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Park Davis Pharmaceutical Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ACETIC ACIDS; ADOLESCENT; ADULT; AGED; AGORAPHOBIA; AMINES; ANTI-ANXIETY AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS;

EID: 0033942108     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200008000-00011     Document Type: Article

References (28)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 1993;51:8-19.
2. Boyd JH, Rae DS, Thompson JW, Burns BJ, Bourdon K, Locke BZ, Regier DA. Phobia: prevalence and risk factors. Soc Psychiatry Psychiatr Epidemiol 1990;25:314-23.
3. Sherbourne CD, Wells KB, Judd LL. Functioning and well-being of patients with panic disorder. Am J Psychiatry 1996;153:213-8.
4. Hollander E, Simeon D, Gorman JM. Anxiety disorders. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of psychiatry. 2nd ed. Washington, DC: American Psychiatric Press, 1994:495-513.
5. Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorder: a double-blind, placebo-controlled study. Psychopharmacology (Berl) 1982; 77:229-33.
6. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SR, Goetz D, Klein DF. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986;6:13-20.
7. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold J, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results form a multicenter trial: 1. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-22.
8. Wilkinson G, Balestrieri M, Ruggeri M, Bellantuono C. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991;21:991-8.
9. Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O'Neil PM, Ballenger JC. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993;29:183-8.
10. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
11. Westenberg HG. Developments in the drug treatment of panic disorder what is the place of the selective serotonin reuptake inhibitors? J Affect Disord 1996;40:85-93.
12. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.
13. Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997;153[Suppl 1]:S39-S45.
14. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996;127:1-9.
15. Dimond KR, Pande AC, LaMoreaux L, Pierce MW. Effects of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20: 407-17.
16. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
17. Chouinard G, Beauclair L, Belanger M-C. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders [letter]. Can J Psychiatry 1998; 43:305.
18. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The panic and agoraphobia scale. Int Clin Psychopharmacol 1995;10:73-81.
19. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E. Comparison of aerobic exercise, clomipramine, and placebo in treatment of panic disorder. Am J Psychiatry 1998;155:603-9.
20. Hamilton MW. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:10-6.
21. Hamilton MW. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-60.
22. Guy W. ECDEU assessment manual for psychopharmacology. Publication No. ADM 76-338. Washington, DC: Department of Health, Education and Welfare, 1976:217-22.
23. Marks I, Matthews A. Brief standard self-rating for phobia patients. Behav Res Ther 1979;17:263-7.
24. SAS Institute, Inc. SAS/STAT software. Changes and enhancements through release 6.12. Cary, NC: SAS Institute, Inc., 1996.
25. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-50.
26. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-6.
27. Keck PE Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-6.
28. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1998;145:1104-9.